NCT06894771View on ClinicalTrials.gov

A Study of MK-4700 Alone or With Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors (MK-4700-001)

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

82

Participants

Timeline

Start Date

April 23, 2025

Primary Completion Date

November 24, 2025

Study Completion Date

November 24, 2025

Conditions
Malignant Neoplasm
Interventions
BIOLOGICAL

MK-4700

Administered via subcutaneous (SC) injection

BIOLOGICAL

Pembrolizumab

Administered via intravenous infusion

Trial Locations (7)

78229

NEXT Oncology ( Site 0300), San Antonio

3109601

Rambam Health Care Campus ( Site 0201), Haifa

4941492

Rabin Medical Center ( Site 0202), Petah Tikva

5265601

Sheba Medical Center ( Site 0200), Ramat Gan

07601

John Theurer Cancer Center at Hackensack University Medical Center ( Site 0301), Hackensack

M5G 2M9

Princess Margaret Cancer Center ( Site 0101), Toronto

G1J 1Z4

Centre intégré de cancérologie du CHU de Québec Université Laval, Hôpital de l'Enfant-Jésus ( Site 0102), Québec

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT06894771 - A Study of MK-4700 Alone or With Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors (MK-4700-001) | Biotech Hunter | Biotech Hunter